Colorectal Cancer - Heat Map and Analysis
 |
| Colorectal Cancer |
Albany, New York, Mar 15, 2017
"Colorectal
Cancer - Heat Map and Analysis 2017"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Colorectal
cancer (CRC), otherwise known as bowel cancer, is a malignancy
originating in the colon (the large intestine) or rectum, both of
which are located towards the end of the human gastrointestinal
tract. It begins as a benign tumor, which is almost always in the
form of a small polyp within the colon or rectum. It rarely occurs in
the absence of polyps, although can arise as a result of an
inflammatory bowel disease such as Crohn’s disease or ulcerative
colitis. CRC was the third most prolific oncological indication with
regard to the number of new cases in the US in 2017.
The
disease can be divided into two categories based on how advanced it
is upon diagnosis. These are early-stage (adjuvant) CRC, which can be
treated with surgery, and metastatic (advanced) CRC, which cannot.
Therapeutic options differ between the two treatment settings, with
therapies for adjuvant CRC aiming to prevent disease re-occurrence
and those for advanced conditions aiming to slow disease progression
while maintaining the patient’s quality of life.
Targeted therapies have already begun to extend
the lifespan of metastatic CRC patients compared with
chemotherapy-only regimens. However, there remains an unmet need to
improve the efficacy of treatment options and extend survival for
these patients. Additionally, an unmet need exists for patients with
KRAS mutation-positive CRC, for whom certain currently marketed
therapies are not recommended.
This tabular heatmap framework, designed to
provide an easily digestible summary of these clinical
characteristics, provides detailed information on all late-stage
clinical trial results for products in the CRC market, with
additional focus on the late-stage pipeline. These are split along
therapy lines, and are therefore reflective of the treatment
algorithm.
All safety and efficacy endpoints reported in
these trials are displayed, for both the drug and placebo groups. In
addition, key study characteristics such as the size, composition and
patient segment of the study population are provided. These results
are presented in a visually accessible, color-coded manner in order
to maximize ease of use.
The accompanying text provides a detailed analysis
of the clinical benchmarks set by the current market landscape, and
the anticipated changes to these benchmarks, and to the treatment
algorithm, as a result of the late-stage pipeline.
** Scope
- How is the colorectal cancer market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?
- What are the clinical characteristics of currently approved therapies for colorectal cancer, in terms of specific safety and efficacy parameters?
- How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?
- How will current late-stage immunotherapeutics affect the colorectal cancer market, and will they be able to satisfy current unmet need with regard to effective therapy options?
- Are future product approvals likely to affect the treatment algorithm significantly?
** Reasons to buy
- Understand the current clinical landscape by considering the treatment options available for earlyand late-stage disease.
- Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
- Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
- Understand the relative strengths and weaknesses of the studies used to gather these data.
- Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
- Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.
Comments
Post a Comment